US Stock Insider Trading | Ardelyx disclosed 18 insider transactions on February 23

K-LinePoet · 2026-02-24T02:08:54+00:00

On February 23, 2026, Ardelyx disclosed multiple insider transactions, including Director RAAB MICHAEL selling 40,400 shares on February 20, and other executives also conducted transactions. Ardelyx is a biopharmaceutical company focused on non-systematic small molecule drugs, dedicated to developing new medications in areas such as gastrointestinal diseases.

K-LinePoet

2026-02-24 02:08:54

Abstract generation in progress

On February 23, 2026, Ardelyx (ARDX) disclosed 18 insider trading transactions. Director Michael Raab sold 40,400 shares on February 20, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
2026-02-23	Director	Michael Raab	2026-02-20	Sell	40,400	5.87	237,000
2026-02-23	Executive	Eric Duane Foster	2026-02-20	Sell	1,261	5.71	7,205.10
2026-02-23	Director	Michael Raab	2026-02-20	Sell	1	5.70	5.70
2026-02-23	Director	Michael Raab	2026-02-20	Sell	5,576	5.71	31,900
2026-02-23	Executive	Eric Duane Foster	2026-02-20	Sell	1	5.70	5.70
2026-02-23	Executive	Eric Duane Foster	2026-02-20	Sell	1	5.71	5.71
2026-02-23	Director	Michael Raab	2026-02-20	Sell	2	5.70	11.40
2026-02-23	Director	Michael Raab	2026-02-20	Sell	2	5.70	11.40
2026-02-23	Executive	Susan Hohenleitner	2026-02-20	Sell	247	5.71	1,411.31
2026-02-23	Executive	Eric Duane Foster	2026-02-20	Sell	9,176	5.87	53,800

【Company Information】

Ardelyx, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and commercializing innovative, non-systemic small molecule therapies, primarily targeting gastrointestinal, cardiometabolic, and kidney diseases. The company’s drug discovery and design platform enables it to identify and develop new candidate drugs quickly and cost-effectively. The company was incorporated in Delaware on October 17, 2007, and was renamed Ardelyx in June 2008.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.